Repeat Biopsy for Mutational Analysis of Non–Small Cell Lung Cancers Resistant to Previous Chemotherapy: Adequacy and Complications

Abstract

When performed by employing rigorous CT criteria, rebiopsies for the mutational analysis of NSCLCs treated previously with chemotherapy are feasible in all patients and are adequate in approximately four-fifths of patients referred for gene analysis, with acceptable rates of complications.